received no comments on this proposal. Therefore, the Bureau adopts its proposal.

71. Finally, the Bureau notes that in the event of a default, the Commission may reauction the license or offer it to the next highest bidder (in descending order) at its final bid amount. In addition, if a default or disqualification involves gross misconduct, misrepresentation, or bad faith by an applicant, the Commission may declare the applicant and its principals ineligible to bid in future auctions, and may take any other action that it deems necessary, including institution of proceedings to revoke any existing licenses held by the applicant.

F. Refund of Remaining Upfront Payment Balance

72. All upfront payments submitted by applicants in Auction 77 may be available to be refunded after the conclusion of the auction; subject to any required payments (i.e. winning bid, deficiency, and/or default payments). All refunds will be returned to the payer of record, as identified on the FCC Form 159, unless the payer submits written authorization instructing otherwise.

Federal Communications Commission.

Gary D. Michaels,
Deputy Chief, Auctions Spectrum and Access Division, WTB.
[FR Doc. E8–10381 Filed 5–7–08; 8:45 am]

BILLING CODE 6712–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day–08–0106]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an e-mail to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice.

Proposed Project

Preventive Health and Health Services Block Grant—Revision—National Center for Chronic Disease and Public Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The Preventive Health and Health Services Block Grant program provides awardees with their primary source of flexible funding for health promotion and disease prevention programs. Sixty-one awardees (50 states, the District of Columbia, two American Indian Tribes, and eight U.S. territories) currently receive block grants from CDC in order to address locally defined public health needs in innovative ways. Block Grants allow awardees to prioritize the use of funds to fill funding gaps in programs that deal with leading causes of death and disability, as well as the ability to respond rapidly to emerging health issues.

CDC currently collects standardized application and performance information from each awardee through an electronic Grant Application and Reporting System (GARS). In response to measures described in the Government Performance Results Act, CDC proposes to replace GARS with a web-based Block Grant Management Information System (BG-MIS) that will collect information by the areas described in Healthy People 2010 and improve adherence to its goals. Concurrent with conversion to the BG-MIS, minor changes to the questions and response options, and other features, will be implemented to reduce respondent burden and support the Healthy People 2010 framework. These features include increased utilization of pre-defined response options, start and end dates, the SMART (Specific, Measurable, Achievable, Realistic, and Time-based) format for describing objectives, and identification of Evidence Based Guidelines and Best Practices used as the basis for public health programs and interventions. In addition, a Compliance Review section has been added to provide each awardee with general information regarding the Compliance Review process and specific information pertaining to its past reviews.

Information will be collected twice per year. Each awardee will submit an annual Work Plan outlining awardee-specific health outcome objectives and an Annual Report describing progress toward its goals.

There are no costs to respondents except their time. The estimated annualized burden hours are 3,355.

ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Respondents</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHHS Block Grant Awardees</td>
<td>Work Plan</td>
<td>61</td>
<td>1</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Annual Report</td>
<td>61</td>
<td>1</td>
<td>30</td>
</tr>
</tbody>
</table>
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Exports: Notification and Recordkeeping Requirements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by June 9, 2008.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–6974, or e-mailed to baguilar@omb.eop.gov. All comments should be identified with the OMB control number 0910–0482. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Exports: Notification and Recordkeeping Requirements—(OMB Control Number 0910–0482)—Extension

The respondents to this information collection are exporters who have notified FDA of their intent to export unapproved products that may not be sold or marketed in the United States as allowed under section 801(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 381(e)). In general, the notification identifies the product being exported (e.g. name, description, and in some cases, country of destination) and specifies where the notification should be sent. These notifications are sent only for an initial export; subsequent exports of the same product to the same destination (or, in the case of certain countries identified in section 802(b) of the act (21 U.S.C. 382(b)), to any of those countries would not result in a notification to FDA.

The recordkeepers to this information collection are exporters who export human drugs, biologics, devices, animal drugs, foods and cosmetics that may not be sold in the United States to maintain records demonstrating their compliance with the requirements in section 801(e)(1) of the act.

The total burden estimate of 39,120 is based on the number of notifications received by the relevant FDA centers in fiscal year 2007, or the last year the figures were available.

In the Federal Register of January 28, 2008 (73 FR 4874), FDA published a 60-day notice requesting public comment on the information collection provisions. No comments were received.

<table>
<thead>
<tr>
<th>21 CFR Section</th>
<th>No. of Respondents</th>
<th>Annual Frequency per Response</th>
<th>Total Annual Responses</th>
<th>Hours per Response</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.101(d) and (e)</td>
<td>400</td>
<td>3</td>
<td>1,200</td>
<td>15</td>
<td>18,000</td>
</tr>
</tbody>
</table>

† There are no capital costs or operating and maintenance costs associated with this collection of information.

<table>
<thead>
<tr>
<th>21 CFR Section</th>
<th>No. of Recordkeepers</th>
<th>Annual Frequency per Recordkeeping</th>
<th>Total Annual Records</th>
<th>Hours per Record</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.101(b) and (c)</td>
<td>320</td>
<td>3</td>
<td>960</td>
<td>22</td>
<td>21,120</td>
</tr>
</tbody>
</table>

† There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: May 1, 2008.

Jeffrey Shuren,
Associate Commissioner for Policy and Planning.

[FR Doc. E8–10204 Filed 5–7–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Anti-Infective Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on July 16, 2008, from 8 a.m. to 5 p.m.

Location: Food and Drug Administration, Center for Drug Evaluation and Research